1. Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC). (December 2013) Authors: Lawrence, Donna; Maschio, Michael; Leahy, Kevin J.; Yunger, Simon; Easaw, Jacob C.; Weinstein, Milton C. Journal: Journal of medical economics Issue: Volume 16:Number 12(2013) Page Start: 1387 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Economic evaluation of rituximab in addition to standard of care chemotherapy for adult patients with acute lymphoblastic leukemia. (2nd January 2018) Authors: Nam, Julian; Milenkovski, Robert; Yunger, Simon; Geirnaert, Marc; Paulson, Kristjan; Seftel, Matthew Journal: Journal of medical economics Issue: Volume 21:Number 1(2018) Page Start: 47 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗